The UK CF Gene Therapy Consortium had a successful day at this year's Medical Futures Innovation Awards on Monday 06 June.
Having been nominated for the awards for our Lentiviral Research Programme the team were successful in first winning the Best Therapeutic Innovation (Respiratory) and then later won the prestigious MRC Translational Research Award.
The project is based around the development of a novel Lentiviral Gene Transfer platform for cystic fibrosis lung disease. Working with DNAVec, a Japanese biotech company we have successfully re-targeted a Simian Immunodeficiency Virus vector to infect previously intractable respiratory epithelial cells.
For more information please visit the UK CF Gene Therapy Consortium Website.